MERTK and leukemia: MRX-2843 and related MERTK TKIs mediate direct tumor cell killing in preclinical models and promote sensitivity to chemotherapy in vitro and in murine models of leukemia, melanoma, lung cancer, and many other malignancies [12,15,17,18,19,20,21,22].